PROSTAGLANDINS & OTHER LIPID MEDIATORS, published by Elsevier Science Inc, is a leading journal dedicated to the advancements in the field of lipid mediators, with a specific focus on prostaglandins and other bioactive lipids. This journal, indexed under ISSN 1098-8823 and E-ISSN 2212-196X, serves as a crucial platform for researchers and professionals to disseminate significant findings that span multiple disciplines, including Biochemistry, Cell Biology, Pharmacology, and Physiology. In the 2023 category quartiles, it has achieved commendable positions such as Q2 in Biochemistry and Q2 in Physiology, underscoring its importance and influence in these domains. Although it is not an open-access journal, it provides robust access options, enhancing the visibility of vital research. With its establishment in 1996, the journal continues its commitment to fostering innovative research until 2024, making it an essential resource for those involved in the dynamic realms of lipid biology and medical research.

Journal of Inflammation-London, published by BMC, is a premier open access journal dedicated to advancing the understanding of inflammation, a critical process underlying numerous diseases including autoimmune disorders, cancer, and cardiovascular conditions. With its inception in 2004, the journal has consistently delivered high-quality research that bridges basic science and clinical applications, maintaining a significant place in the academic community. It holds impressive rankings within the Q2 category for both Cell Biology and Clinical Biochemistry, reflecting its impactful contributions to these fields, where it ranks in the 73rd and 64th percentiles respectively. The journal is committed to open access principles, ensuring that all published articles are freely available to researchers, practitioners, and the global community, thereby fostering collaboration and innovation. Located in the United Kingdom, the journal continues to attract submissions from prominent researchers and institutions worldwide, solidifying its status as an essential resource for the latest developments in inflammation research.

Nature Reviews Gastroenterology & Hepatology is a premier academic journal published by NATURE PORTFOLIO, specializing in the vital fields of gastroenterology and hepatology. With an impressive impact factor and categorized in Q1 for both disciplines, this journal ranks at the top of its field, with Scopus rankings placing it in the 99th percentile for gastroenterology and hepatology. The journal aims to provide critical reviews that synthesize the latest research findings, clinical practices, and breakthroughs, catering to researchers, healthcare professionals, and students alike. With its wide-ranging access options, it promotes the dissemination of knowledge essential for advancements in understanding digestive and liver disorders. The journal has been committed to academic excellence since its convergence in 2009, continuing to shape the future of gastroenterological and hepatological research through rigorous peer-reviewed content.

Journal of Inflammation Research, published by Dove Medical Press Ltd, is a premier open-access journal dedicated to advancing the field of immunology and allergy, with a particular focus on the biological mechanisms underlying inflammation. Since its inception in 2008, this journal has provided a vital platform for researchers to share their findings and foster collaboration within the global scientific community. With an impressive 2023 impact factor placing it in the Q2 category for both Immunology and Immunology and Allergy, the journal has consistently maintained its relevance and high academic standards, ranking #100 in Medicine (Immunology and Allergy) and #118 in Immunology (Immunology and Microbiology) according to Scopus metrics. The E-ISSN 1178-7031 allows for easy access to a plethora of pioneering research articles, reviews, and clinical studies that address contemporary issues in inflammation and immunity. As a leading resource for researchers, professionals, and students alike, Journal of Inflammation Research is committed to facilitating the dissemination of groundbreaking discoveries that contribute to improved therapeutic strategies and health outcomes.

TRENDS IN IMMUNOLOGY, published by CELL PRESS, stands as a premier source of insights and developments within the field of immunology. With an ISSN of 1471-4906 and E-ISSN of 1471-4981, this journal has established a strong reputation, evidenced by its prestigious status in Q1 quartiles for both Immunology and Allergy in 2023. It is ranked #13 out of 233 in the Scopus category of Medicine – Immunology and Allergy, and #16 out of 236 in Immunology and Microbiology, placing it within the top 94th and 93rd percentiles respectively. Since its inception in 1987, TRENDS IN IMMUNOLOGY has provided a critical platform for researchers, professionals, and students to access the latest advancements and integrative reviews in immunological research. The journal offers open access options, enhancing the accessibility of its high-impact content to a global audience. Researchers and practitioners rely on its pages not only for cutting-edge findings but also for comprehensive discussions that drive the future of immunology research.

The Journal of Innate Immunity, published by KARGER, stands at the forefront of immunological research, focusing on the critical role of innate immunity in health and disease. With its Open Access model since 2019, the journal ensures broad dissemination of groundbreaking findings and facilitates global scholarly communication. Based in Switzerland and indexed with an impressive Q1 category ranking in Immunology and Allergy for 2023, it occupies a prominent position in the scientific community, ranked #47 out of 233 in the field. Researchers, professionals, and students alike benefit from accessing high-quality, peer-reviewed articles that span from 2008 and will continue to evolve until 2024, reflecting the latest advances and challenges in innate immunity. As an essential resource, it addresses critical questions and shares innovative insights that push the boundaries of our understanding in this dynamic field.

JOURNAL OF CLINICAL INVESTIGATION is a premier scholarly journal published by the American Society for Clinical Investigation, dedicated to advancing the field of clinical research and medicine since its inception in 1945. With an impressive impact factor and ranked Q1 in the field of Medicine (miscellaneous), it stands out as a leading source of high-quality research, reflecting its exceptional position in Scopus ranking as #13 out of 636 in General Medicine, placing it in the 98th percentile. The journal focuses on groundbreaking studies that explore the underlying mechanisms of human disease, facilitating a deeper understanding that drives clinical practice and innovation. Although it is not an open-access journal, the insights and findings published in this esteemed journal are essential reading for researchers, healthcare professionals, and students aspiring to contribute to the dynamic landscape of clinical investigation. Published in the United States, it continues to shape the dialogue and advancement within the medical community through its rigorous peer-review process and commitment to excellence.

Central European Journal of Immunology is a premier publication dedicated to advancing the field of immunology and allergy research. Established in 1996 and published by TERMEDIA PUBLISHING HOUSE LTD, this open access journal has consistently provided a platform for innovative research and comprehensive reviews since its transition to open access in 2002. With an ISSN of 1426-3912 and E-ISSN of 1644-4124, it embraces a global readership while being rooted in Poland. The journal, with a notable Q3 ranking in both the categories of immunology and allergy in 2023, positions itself within the competitive landscape of scientific discourse, as reflected in its Scopus rankings. Designed for researchers, professionals, and students, the Central European Journal of Immunology not only disseminates significant findings but also fosters collaboration and innovation in the immunological sciences, making it a vital resource for those seeking to stay current in this rapidly evolving field.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, published by Lippincott Williams & Wilkins, is a leading journal in the field of cardiovascular medicine, dedicated to the advancement of research surrounding arterial diseases, thrombosis, and vascular biology. With an impressive impact factor indicative of its reach and influence, this journal occupies a prominent position in the Q1 category of cardiology, ranking 13th out of 387 in its field according to Scopus, placing it within the top 96th percentile among cardiovascular research journals. Since its inception in 1990, ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY has been pivotal in disseminating cutting-edge research that drives innovation and education in cardiovascular health. Although it does not operate under an open access model, the journal is a vital resource for researchers, clinicians, and students looking for high-quality, peer-reviewed articles that contribute to the understanding and treatment of cardiovascular and vascular disorders. Its commitment to rigorous scientific standards and its focus on impactful findings make it an essential publication for anyone dedicated to the field.

INFLAMMOPHARMACOLOGY is a premier journal published by SPRINGER BASEL AG, specializing in the evolving fields of immunology and pharmacology. Established in 1991, the journal has made significant strides in contributing to the understanding of inflammation-related disorders, therapeutic innovations, and the pharmacological implications associated with these conditions. With an impressive Q2 ranking in Immunology and Q1 rankings in both Pharmacology and Medical Pharmacology for 2023, alongside notable Scopus rankings, INFLAMMOPHARMACOLOGY maintains its position at the forefront of scientific research. The journal provides a vital platform for researchers and practitioners to disseminate groundbreaking findings and explore novel approaches in therapeutics, reinforcing the importance of evidence-based medicine. Accessible exclusively through traditional subscription options, it continues to attract a diverse readership invested in advancing knowledge within these cutting-edge disciplines.